DV
Dividend Vision

SLS — SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. (SLS)

Total return is -100.0% over the past 18.4 years, 829.8 points behind SPY at 729.8%. Its deepest 1-year drawdown was 36.2%.

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel cancer therapeutics, with lead candidates including galinpepimut-S (GPS), a peptide immunotherapy targeting Wilms tumor 1 antigen, and SLS009 (tambiciclib), a selective CDK9 inhibitor. The company does not currently distribute dividends. SELLAS operates through strategic collaborations including partnerships with Merck & Co. to evaluate GPS in combination with pembrolizumab across multiple cancer indications, and with Memorial Sloan Kettering Cancer Center for WT1 peptide vaccine development.

SLS key facts

Asset type
Stock
Asset class
Equity
Inception date
03/12/2008
Last close
$12.78
Market cap
$2,580,866,048
Average volume
4393200.0
Payment date
11/08/2019
Beta
2.494
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.22